ABSTRACT
The relationships between the Platelet Function Analyzer (PFA)-100 and von Willebrand factor (VWF) levels and bleeding score (BS) were evaluated within a multicentre project on Molecular and Clinical Markers for the Diagnosis and Management of type 1 von Willebrand disease (MCMDM-1VWD). PFA-100 closure time, either with epinephrine (EPI) or adenosine diphosphate (ADP)-cartridges, was measured in 107 index cases, 105 affected and 71 unaffected family members, and 79 healthy controls. By regression analysis VWF levels were strongly related to both closure times, with a non-linear progression. In a multiple stepwise regression model, age- and sex-adjusted PFA-100 ADP and VWF ristocetin cofactor activity (VWF:RCo) were independently associated with BS. Most of the variation of BS was predicted by PFA-100 ADP and VWF:RCo alone. In the subgroup of patients with subtle abnormalities of the multimeric pattern, VWF was invariably reduced and closure time prolonged in almost all of them. Neither PFA-100 ADP nor EPI closure times appeared to significantly improve the diagnostic capability of VWF antigen (VWF:Ag) measurement. Thus, in an unselected population a normal PFA-100 would be useful to exclude VWD, but whether it could replace the more specific VWF assay in patients with significant mucocutaneous bleeding symptoms remains to be investigated prospectively.
Subject(s)
von Willebrand Diseases/diagnosis , von Willebrand Factor/analysis , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Child , Child, Preschool , Female , Genetic Linkage , Humans , Infant , Male , Middle Aged , Phenotype , Platelet Function Tests , Reference Values , von Willebrand Diseases/genetics , von Willebrand Factor/geneticsABSTRACT
The decreased survival of von Willebrand factor (VWF) in plasma has been implicated as a mechanism in a subset of type 1 von Willebrand disease (VWD) patients. We have previously reported that the ratio of plasma levels of VWF and its propeptide (VWFpp) can be used to identify patients with reduced VWF survival. In this study, we report the assay of VWFpp and VWF:Ag in 19 individuals recruited from 6 European centers within the MCMDM-1VWD study. Eight individuals had a VWF:Ag level less than 30 IU/dL. Seven of these patients had a robust desmopressin response and significantly reduced VWF half-life that was predicted by a markedly increased steady-state plasma VWFpp/VWF:Ag ratio. VWF mutations previously associated with reduced VWF survival were identified in each of the 7 individuals. Thus, a substantially increased ratio of steady-state VWFpp/VWF:Ag predicted a reduced VWF half-life in patients with markedly decreased VWF:Ag levels. These data indicate that a reduced VWF survival is found in a subpopulation of patients with type 1 VWD. The systematic assay of both plasma VWF and the VWF propeptide in moderately severe type 1 VWD patients may identify patients with a reduced VWF survival phenotype.
Subject(s)
Protein Precursors/blood , von Willebrand Diseases/diagnosis , von Willebrand Diseases/mortality , von Willebrand Factor/analysis , Biomarkers/blood , Deamino Arginine Vasopressin/therapeutic use , Europe , Half-Life , Humans , Mutation , Predictive Value of Tests , Survival Analysis , Treatment OutcomeABSTRACT
We have prospectively evaluated the biologic response to desmopressin in 77 patients with type 1 von Willebrand disease (VWD) enrolled within the Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD project. Complete response to desmopressin was defined as an increase of both ristocetin cofactor activity (VWF:RCo) and factor VIII coagulant activity (FVIII:C) to 50 IU/dL or higher and partial response as VWF:RCo or FVIII:C lower than 50 IU/dL after infusion, but at least 3-fold the basal level. Complete response was observed in 83% of patients; partial in 13%; and no response in 4%. Patients with some abnormality of VWF multimeric pattern had significantly lower basal FVIII:C and VWF, lower VWF:RCo/Ag ratio, and less complete responses to desmopressin than patients with a normal multimeric pattern (P=.002). Patients with mutations at codons 1130 and 1205 in the D'-D3 domain had the greatest relative increase, but shortest FVIII and VWF half-lives after infusion. Most partial and nonresponsive patients had mutations in the A1-A3 domains. Response to desmopressin in these VWD patients seemed to be associated with the location of the causative mutation. The presence of subtle multimeric abnormalities did not hamper potential clinically useful responses, as in typical type 1 VWD.
Subject(s)
Deamino Arginine Vasopressin/administration & dosage , Hemostatics/administration & dosage , von Willebrand Diseases/drug therapy , von Willebrand Diseases/genetics , Adolescent , Adult , Aged , Blood Coagulation Tests/methods , Child , Factor VIII/analysis , Factor VIII/chemistry , Female , Genotype , Humans , Male , Middle Aged , Mutation , Prospective Studies , Protein C/analysis , Protein C/chemistry , Protein Structure, Tertiary/genetics , Ristocetin/chemistryABSTRACT
Two versions of conformation sensitive gel electrophoresis, fluorescent (F-CSGE) and manual (M-CSGE) techniques, were compared for mutation analysis of the von Willebrand factor gene. 56 PCRs were used to amplify all 52 exons of the gene in seven type 1 von Willebrand disease cases, plus a healthy control. One hundred and ninety-two samples were analyzed on each F-CSGE gel, compared with 40 on M-CSGE. 125 amplicons revealed bandshifts using F-CSGE, but only 101 by M-CSGE. Five mutations were detected by both techniques. F-CSGE detected 45 different polymorphisms whereas M-CSGE detected only 39. F-CSGE is high-throughput and more sensitive than M-CSGE.
Subject(s)
DNA Mutational Analysis/methods , DNA/genetics , Electrophoresis, Polyacrylamide Gel/methods , Heteroduplex Analysis/methods , Nucleic Acid Conformation , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , DNA/blood , DNA/chemistry , Exons/genetics , Fluorescent Dyes/analysis , Fluorometry , Humans , Polymerase Chain Reaction , Polymorphism, Single Nucleotide , Pseudogenes , Sensitivity and Specificity , von Willebrand Factor/chemistryABSTRACT
Type 1 von Willebrand disease (VWD) is characterized by a personal and family history of bleeding coincident with reduced levels of normal plasma von Willebrand factor (VWF). The molecular basis of the disorder is poorly understood. The aims of this study were to determine phenotype and genotype and their relationship in patients historically diagnosed with type 1 VWD. Families were recruited in 9 European countries based on previous type 1 VWD diagnosis. Bleeding symptoms were recorded, plasma phenotype analyzed, and VWF mutation analysis performed in all index cases (ICs). Phenotypic and molecular analysis stratified patients into those with or without phenotypes suggestive of qualitative VWF defects (abnormal multimers) and with or without mutations. A total of 105 of 150 ICs (70%) had mutations identified. A subgroup with abnormal multimers (38% of ICs, 57 of 150) showed a high prevalence of VWF gene mutations (95% of ICs, 54 of 57), whereas in those with qualitatively normal VWF, fewer mutations were identified (55% of ICs, 51 of 93). About one third of the type 1 VWD cases recruited could be reconsidered as type 2. The remaining group could be considered "true" type 1 VWD, although mutations were found in only 55%.
Subject(s)
von Willebrand Diseases/epidemiology , von Willebrand Factor/genetics , ABO Blood-Group System/genetics , Alleles , Amino Acid Substitution , Biopolymers , Blood Coagulation Tests , Cohort Studies , DNA Mutational Analysis , Europe , Factor VIII/analysis , Family Health , Female , Gene Frequency , Genotype , Health Surveys , Hemorrhage/epidemiology , Hemorrhage/etiology , Humans , Male , Mutation, Missense , Phenotype , Point Mutation , Prevalence , Promoter Regions, Genetic/genetics , RNA Splice Sites/genetics , Severity of Illness Index , Surveys and Questionnaires , von Willebrand Diseases/blood , von Willebrand Diseases/classification , von Willebrand Diseases/genetics , von Willebrand Factor/analysisABSTRACT
Type 2N von Willebrand disease (VWD) is characterized by a markedly decreased affinity of von Willebrand factor (VWF) for factorVIII (FVIII) and is caused by mutations in the D' or D3 domain of mature VWF. We now report a French patient with an atypical 2N VWD phenotype associating FVIII deficiency with plasmaVWF unable to bind FVIII (undetectableVWF:FVIIIB) but with an abnormal multimeric profile. This patient is heterozygous for both the frequent R854Q type 2NVWD mutation and a novel R763G mutation at the cleavage site between VWF propeptide and mature VWF. Four children of the patient displayed moderately decreased VWF:FVIIIB of plasma VWF and were heterozygous for either the R763G or the R854Q mutation. Children with the R763G mutation displayed the same abnormal multimeric profile as their father. Recombinant VWF (rVWF) expression studies performed in COS-7 cells showed that the R763G mutation subtly affects its multimeric profile and dramatically impairs its FVIII binding function. Furthermore, the characteristics of hybrid G763/Q854 rVWF resulting from cotransfection experiments were in agreement with the type 2N VWD diagnosis of the patient. We conclude that R763G is a new type 2N VWD mutation located in the VWF propeptide which alters the proteolytic processing of VWF and consequently its binding to FVIII.
Subject(s)
Factor VIII/chemistry , Heterozygote , Mutation , Peptides/chemistry , von Willebrand Diseases/diagnosis , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , Aged , Animals , Binding Sites , COS Cells , Chlorocebus aethiops , Humans , Male , Recombinant Proteins/chemistry , Sequence Analysis, DNAABSTRACT
Different plasma-derived products have been used to treat patients affected with von Willebrand disease (vWD). To ensure optimal product selection, the purification process and viral elimination methods should be considered. Unfortunately, details regarding the degree of purification and viral attenuation achieved for each product typically are limited to the information provided by the package insert. Recently published studies have compared the in vitro characteristics of some of these products. All vary in terms of protein composition, proteins copurified with von Willebrand factor (vWF) and factor (F) VIII, and the characteristics of the active substance. There currently remains a lack of consensus regarding the in vitro characteristics essential to ensure a concentrate optimized for the treatment of vWD. We suggest that the minimal requirements for products on the market for the substitutive treatment of vWD are that they must (1) have the same level of safety in terms of eliminating the potential of blood-borne infections provided by plasma-derived products currently available for hemophilia A patients, (2) contain vWF that promotes adhesion and aggregation of platelets as well as transport and stabilization of FVIII, (3) have been tested for pharmacokinetics and efficacy in patients with different types of vWD before their clinical use for this indication, and (4) be labeled with both vWF and FVIII potency.
Subject(s)
Biological Products/therapeutic use , Plasma , von Willebrand Diseases/therapy , Biological Products/standards , Blood Proteins/therapeutic use , Factor VIII/analysis , Humans , Quality Assurance, Health Care , Quality Control , Safety , von Willebrand Diseases/bloodABSTRACT
Type 2B von Willebrand disease (VWD) is characterised by an increased affinity of von Willebrand factor (VWF) for its platelet receptor glycoprotein Ib (GPIb). This feature is usually studied in vitro by a ristocetin-dependent VWF platelet-binding assay, which has some limitations as it requires [e.g. (radio)-labelled anti-VWF antibodies and normal formaldehyde-fixed platelets]. We, here, extended the applicability of an enzyme-linked immunosorbent assay-based method previously described for the measurement of ristocetin co-factor activity that used a recombinant fragment of GPIb (rfGPIb alpha) and horseradish peroxidase-labelled rabbit anti-human VWF antibodies for measuring the captured ristocetin-VWF complexes on the rfGPIb alpha. Thirty-one type 2B VWD patients from 15 families with eight different known mutations were studied. VWF in plasma from 28 of these patients bound better than normal VWF at 0.2 mg/ml ristocetin, with the ratio, optical density (OD) patient/OD normal pool plasma, higher than 1.8. For two of the three other patients with no enhanced response of plasma VWF, the platelet lysate VWF showed an enhanced binding capacity; for the last patient, the results in other members of the family are unequivocal. We conclude that, this new method for measurement of plasma or platelet VWF-binding capacity offers great advantages for correct type 2B VWD diagnosis.
Subject(s)
Platelet Glycoprotein GPIb-IX Complex/metabolism , von Willebrand Diseases/diagnosis , von Willebrand Factor/metabolism , Adolescent , Adult , Aged , Blood Platelets/metabolism , Child , Child, Preschool , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay/methods , Humans , Infant , Middle Aged , Platelet Count , Recombinant Proteins/metabolism , Ristocetin/pharmacology , von Willebrand Diseases/bloodABSTRACT
The CK domain of von Willebrand factor (VWF) is involved in the dimerization of the protein. We identified the homozygous substitution A2801D of the CK domain in two siblings. Patients had low levels of VWF in plasma, abnormal ristocetin-induced binding to platelets and abnormal multimeric pattern with a lack of high molecular weight (HMW) forms and the presence of intervening bands between normal multimers. Accordingly, they were classified in type 2A, subtype IID, von Willebrand disease (VWD). Both asymptomatic parents carried the mutation at the heterozygous state. Their plasmaVWF exhibited the full range of multimers found in normal plasma. When analyzed by high resolution gel electrophoresis, very faint bands corresponding to the position of intervening bands of the propositus can be observed. The mutated recombinant (r)VWF-D2801, the hybrid rVWF-A/D2801 and the mutated C-terminal VWF fragment rSPII-D2801 were expressed in COS-7 cells. rVWF-D2801 showed an abnormal multimeric distribution similar to that of the propositus'VWF with intervening bands and a lack of HMW species. rVWF-A/D2801 exhibited the full range of multimers and the aberrant sized forms observed both in propositus'VWF and in rVWF-D2801. rSPII-WT assembled correctly into a dimer of 220 kDa. rSPII-D2801 appeared as a mixture of monomeric and dimeric forms which may be related to the abnormal multimeric pattern of the propositus and both mutated rVWF. We concluded that mutation A2801D disturbs the folding of the CK domain, which may result in a mixture of monomers and dimers of VWF. Multimers containing either an odd or even number of mature subunits are produced, and the presence of monomers appears to limit the degree of multimerization. In the heterozygousVWF, the presence of normal dimers improves the multimerization process. In conclusion, the mutation A2801D appears to be responsible for a recessive type 2A, subtype IID, VWD.
Subject(s)
Mutation, Missense , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , Adult , Aged , DNA Mutational Analysis , Dimerization , Family Health , Heterozygote , Humans , Middle Aged , Protein Structure, Tertiary , Protein Subunits , von Willebrand Diseases/classification , von Willebrand Diseases/etiology , von Willebrand Factor/metabolismABSTRACT
Factor XI (FXI) deficiency is an inherited autosomal recessive disorder associated with bleeding of variable severity. However, many cases of dominant disease transmission have been recently described. This disorder is rare in the general population, whereas it is commonly found in individuals of Ashkenazi Jewish ancestry. This study reports the molecular genetic analysis of FXI deficiencies in 11 unrelated families of different origin. Five novel mutations have been identified. Severe FXI deficiency of two unrelated patients resulted from two novel mutations: one deletion (960-961delGT) in exon 9 predicting a frameshift, and a Ser-4Leu mutation located in the signal peptide. In addition, three novel missense mutations associated with partial FXI deficiency have been identified: Cys122Tyr, Glu297Lys and Glu579Lys.
Subject(s)
Factor XI Deficiency/genetics , Factor XI/genetics , Mutation/genetics , Adult , Aged , Base Sequence/genetics , Factor XI Deficiency/metabolism , Female , Humans , Male , Molecular Sequence Data , Mutation/physiology , Polymorphism, GeneticABSTRACT
Type 2N von Willebrand disease (VWD) refers to patients with a factor VIII (FVIII) deficiency caused by a markedly decreased affinity of von Willebrand factor (VWF) for FVIII. It is inherited as an autosomal recessive trait but is clinically similar to mild hemophilia. The differential biologic diagnosis, which is of major importance for providing relevant genetic counseling and optimal treatment, is based on the measurement of plasma VWF capacity to bind FVIII. Molecular biology techniques have allowed the identification of 20 missense mutations in the VWF gene that cause type 2N VWD. All of them induce changes in amino acid residues located in the N-terminal part of mature VWF, which contains the FVIII binding site. Their identification may provide a genetic diagnosis. Theoretically, patients with type 2N VWD should be treated with products containing VWF that is able to stabilize their endogenous normal FVIII.
Subject(s)
von Willebrand Diseases/classification , Female , Humans , Mutation , Pregnancy , Pregnancy Complications, Hematologic , Prevalence , von Willebrand Diseases/diagnosis , von Willebrand Diseases/epidemiology , von Willebrand Diseases/therapy , von Willebrand Factor/genetics , von Willebrand Factor/metabolismABSTRACT
Replacement therapy is the treatment of choice for patients with von Willebrand disease who are unresponsive to desmopressin. In order to prevent transmission of non-enveloped viruses, a solvent/detergent-treated plasma-derived von Willebrand factor available in France since 1989 has been subjected to additional removal/inactivation steps by 35 nm filtration and dry heating for 72 h at 80 degrees C. This preclinical study evaluates the potential immunogenicity of this new product by comparing the antibodies raised in pigs affected with von Willebrand disease after intravenous injection of either a solvent/detergent-treated product or a triple-secured product. Our data showed that there is no difference between the two products in terms of the rate and intensity of the humoral response measured by both binding and neutralizing antibody levels. It was concluded that no antigenic alterations of von Willebrand factor molecules during the nanofiltration and final dry-heating steps were detected in our animal model.
Subject(s)
Antibodies/blood , von Willebrand Diseases/immunology , von Willebrand Factor/chemistry , von Willebrand Factor/immunology , Animals , Antibodies/chemistry , Antibodies/immunology , Antibody Formation/immunology , Disease Models, Animal , Dose-Response Relationship, Immunologic , Humans , Immunization , Injections, Intravenous , Swine , von Willebrand Diseases/blood , von Willebrand Factor/administration & dosageABSTRACT
BACKGROUND AND OBJECTIVES: Type 2A von Willebrand's disease (VWD) refers to disease variants with decreased platelet-dependent function of von Willebrand factor (VWF) associated with the absence of high molecular weight (HMW) multimers. The candidate G1629R mutation, identified in an Italian patient with type 2A VWD, was expressed to confirm the relationship between phenotype and genotype. DESIGN AND METHODS: Plasma samples from the patient were studied after DDAVP or FVIII/VWF concentrate injections. Furthermore, an expression vector carrying the G1629R mutation was constructed by site-directed mutagenesis and transiently expressed in Cos-7 cells. The characteristics of the corresponding recombinant protein were analyzed. RESULTS: After 1-deamino-8-D-argine vasopressin (DDAVP) infusion, factor VIII and VWF activities increased and HMW VWF multimers were transiently observed in the patient's plasma. VWF activity increased only after administration of a dual FVIII/VWF concentrate. ADAMTS-13 activity did not change significantly before or after the therapies. Secretion, in culture medium, of the corresponding mutated protein (R1629-rVWF) was slightly decreased and this rVWF contained intermediate and HMW multimers. Furthermore, binding of R1629-rVWF to platelet GPIb was moderately reduced compared to that of the wild-type rVWF. INTERPRETATION AND CONCLUSIONS: Based on the DDAVP and in vitro expression results, we classified the G1629R mutation in group 2 type 2A mutations. Our findings could explain why DDAVP may only be partially effective and suggest that FVIII/VWF concentrates should be used in cases of prolonged mucosal bleeding and major surgery when functional VWF is required.
Subject(s)
Amino Acid Substitution , Mutation, Missense , Point Mutation , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , ADAM Proteins/blood , ADAMTS13 Protein , Animals , Biopolymers , Blood Coagulation Tests , Blood Platelets/metabolism , COS Cells , Chlorocebus aethiops , Deamino Arginine Vasopressin/pharmacology , Drug Combinations , Drug Resistance , Factor VIII/therapeutic use , Genotype , Gingival Hemorrhage/etiology , Humans , Molecular Weight , Phenotype , Protein Binding , Protein Structure, Tertiary , Recombinant Fusion Proteins/chemistry , Tooth Extraction/adverse effects , von Willebrand Diseases/classification , von Willebrand Diseases/drug therapy , von Willebrand Factor/chemistry , von Willebrand Factor/therapeutic useSubject(s)
von Willebrand Diseases/genetics , von Willebrand Factor/genetics , Binding Sites/genetics , Factor VIII/metabolism , Female , Hemophilia A/blood , Hemophilia A/genetics , Humans , Male , Mutation , von Willebrand Diseases/blood , von Willebrand Diseases/classification , von Willebrand Factor/chemistry , von Willebrand Factor/physiologyABSTRACT
This study prospectively evaluated the rate of biologic response to desmopressin (DDAVP) in 66 patients with type 1 or 2 von Willebrand disease (VWD), each of whom had, on the basis of available records, a clinically significant bleeding history and at least one of the following laboratory abnormalities: bleeding time (BT) longer than 15 minutes, ristocetin cofactor activity (VWF:RCo) less than 10 IU/dL, factor VIII coagulant activity (FVIII:C) less than 20 IU/dL (severe VWD). Before the study, responsive patients were defined as those who, 2 hours after infusion of 0.3 microg/kg DDAVP, had increased baseline values of VWF:RCo and FVIII:C by at least 3-fold and achieved levels of at least 30 IU/dL for both and a BT of 12 minutes or less. The rate of biologic response varied according to VWD types and was higher in type 1 (7 of 26, 27%) than in type 2 (7 of 40, 18%) (type 2A [1 of 15, 7%], type 2M [3 of 21, 14%], type 2N [3 of 4, 75%]). Mutations in the VWF gene were previously known or newly identified in most patients with types 2A (n = 15 of 15), 2M (n = 15 of 21), and 2N (n = 4 of 4), but in none of those with type 1 VWD. Genotype provided more information than phenotype in predicting individual responses to DDAVP only in patients with 2A and 2N VWD. This prospective study showed that the rate of biologic response to DDAVP is relatively low not only in type 2 but also in type 1 VWD when uniform and stringent criteria for patient selection and responsiveness are applied.
Subject(s)
Deamino Arginine Vasopressin/administration & dosage , Hemostatics/administration & dosage , von Willebrand Diseases/drug therapy , Adolescent , Adult , Aged , Child , Europe , Genotype , Humans , Middle Aged , Phenotype , Point Mutation , Prospective Studies , Severity of Illness Index , Treatment Outcome , von Willebrand Diseases/geneticsABSTRACT
In type 2N von Willebrand disease (VWD), von Willebrand factor (VWF) is characterized by a markedly decreased affinity for Factor VIII (FVIII), and the mutations responsible are essentially located in the D' domain of VWF. We report the identification, in seven unrelated French families, of two novel type 2N VWD mutations, Q1053H and C1060R (Gln290His and Cys297Arg in mature VWF sequence), in exon 24 of the VWF gene. These missense mutations have been identified in the heterozygous, homozygous or hemizygous states. Using site-directed mutagenesis and transient expression in COS-7 cells, we showed that both mutations, although located in the D3 domain of VWF, outside the tryptic fragment containing the FVIII domain, dramatically decrease the binding of VWF to FVIII. In contrast, the R924Q substitution, which was identified in a patient who was heterozygous for C1060R, was shown to be a polymorphism.
Subject(s)
Factor VIII/metabolism , Mutation, Missense , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , Animals , COS Cells , DNA Mutational Analysis/methods , Female , Humans , Male , Mutagenesis, Site-Directed , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , von Willebrand Factor/metabolismABSTRACT
We report the identification of a new mutation in exon 28 of the von Willebrand factor (VWF) gene in two related patients with type 2M von Willebrand disease (VWD). The molecular abnormality changes the Ser 1285 to Phe within the A1 loop of VWF. The S1285F mutation was reproduced by site-directed mutagenesis on the full-length VWF cDNA. The mutated recombinant VWF (rVWF), F1285rVWF, and the hybrid, S/F1285rVWF, were expressed in COS-7 cells. F1285rVWF exhibited a slight decrease of high-molecular-weight multimers and markedly reduced ristocetin- or botrocetin-induced binding of VWF to platelets in association with a decreased binding to botrocetin. The hybrid S/F1285rVWF showed a normal multimeric profile and bound to platelets in a similar way to the patients' plasma VWF, in the presence of ristocetin or botrocetin. Thus, the new S1285F mutation within the A1 loop was responsible for the type 2M VWD observed in these patients, and was involved in the binding of VWF to botrocetin and to platelet glycoprotein Ib (GPIb). Three anti-VWF monoclonal antibodies, with conformational epitopes within the A1 loop but distinct GPIb binding inhibitory properties, showed a different interaction with F1285rVWF. These results indicate that the S1285F substitution alters the folding of the A1 loop and prevents the correct exposure of the VWF binding sites to botrocetin and GPIb.
Subject(s)
Crotalid Venoms/metabolism , Mutation , Platelet Glycoprotein GPIb-IX Complex/metabolism , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , Adult , Animals , Binding Sites/genetics , Blood Platelets/metabolism , COS Cells , Electrophoresis, Polyacrylamide Gel , Humans , Male , Protein Binding/genetics , Protein Folding , Protein Structure, Tertiary , Recombinant Proteins/metabolism , Ristocetin/metabolism , von Willebrand Factor/chemistry , von Willebrand Factor/metabolismABSTRACT
In this study, we reinvestigated a 20-year-old woman, the first cousin of two brothers with severe haemophilia A. This patient was previously assumed to be a carrier of haemophilia A due to her FVIII deficiency. We identified a novel FVIII gene mutation in the family and demonstrated that the FVIII deficiency in this female patient did not result from this gene mutation, but was linked to molecular defects in the von Willebrand factor gene.
Subject(s)
Hemophilia A/genetics , Mutation, Missense , von Willebrand Diseases/genetics , von Willebrand Factor/genetics , Adult , Dosage Compensation, Genetic , Factor VIII/metabolism , Female , Heterozygote , Humans , Male , Pedigree , Protein Binding , von Willebrand Factor/metabolismABSTRACT
An international study involving 26 laboratories assayed two candidate von Willebrand Factor (VWF) concentrates (B and C) for VWF:Antigen (VWF:Ag), VWF:Ristocetin Cofactor (VWF:RCo) and VWF:Collagen binding (VWF:CB) relative to the 4th International Standard Factor VIII/VWF Plasma (4th IS Plasma) (97/586). Estimates of VWF:Ag showed good agreement between different methods, for both candidates, and the overall combined means were 11.01 IU/ml with inter-laboratory variability (GCV) of 10.9% for candidate B and 14.01 IU/ml (GCV 11.8%) for candidate C. Estimates of VWF:RCo showed no significant difference between methods for both candidates and gave overall means of 9.38 IU/ml (GCV 23.7%) for candidate B and 10.19 IU/ml (GCV 24.4%) for candidate C. Prior to the calibration of the candidates for VWF:CB it was necessary to calibrate the 4th IS Plasma relative to local frozen normal plasma pools; there was good agreement between different collagen reagents and an overall mean of 0.83 IU per ampoule (GCV 11.8%) was assigned. In contrast, estimates of VWF:CB in both candidates showed large differences between collagen reagents with inter-laboratory GCV's of 40%. Candidate B (00/514) was established as the 1st International Standard von Willebrand Factor Concentrate by the WHO Expert Committee on Biological Standardisation in November 2001 with assigned values for VWF:Ag (11.0 IU/ampoule) and VWF:RCo (9.4 IU/ampoule). Large inter-laboratory variability of estimates precluded the assignment of a value for VWF:CB.
Subject(s)
von Willebrand Factor/standards , Calibration , Drug Stability , Humans , International System of Units , Internationality , Reference Standards , von Willebrand Factor/analysis , von Willebrand Factor/therapeutic useABSTRACT
The present diagnostic assay for type 2N von Willebrand disease (VWD) is based on the in vitro measurement of the capacity of plasma von Willebrand factor (VWF) to bind exogeneous factor VIII (VWF:FVIIIB). We report a method using only commercially available reagents that is easy to perform. This method has been validated in a cohort of 144 patients with FVIII/VWF ratios < 0.6 using a plasma control mixture representative of intermediate VWF:FVIIIB. In total, 15 patients were diagnosed with markedly decreased VWF:FVIIIB and five patients were shown to have moderately decreased VWF:FVIIIB. Specific type 2N mutations were identified in all these patients.